Why the Invion share price rocketed 225% higher today

The Invion Ltd (ASX:IVX) share price is rocketing higher on Wednesday. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best performers on the Australian share market on Wednesday has been the Invion Ltd (ASX: IVX) share price.

The clinical-stage drug development company's shares rocketed an incredible 225% higher at one stage today. They have since given back a good portion of these gains but are still up 125% at the time of writing.

Why is the Invion share price rocketing higher?

Investors have been fighting to get hold of the company's shares on Wednesday following the release of results from a pre-clinical study undertaken by Hudson Institute of Medical Research.

This study relates to the first batch of its Australian-made Photosoft compound on mice with ovarian cancer.

Photosoft technology is an improved next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours, and stimulates the immune system.

It is a potential alternative to surgery and, in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

The results.

According to today's update, researchers at Hudson Institute analysed both immediate and medium-term effects on tumours and made positive observations.

This includes Photosoft causing the immediate and specific death of tumour tissue, with no apparent adverse effects in the surrounding healthy tissues. Furthermore, researchers found the size of the tumours in animals treated with Photosoft reduced to less than half of their original size over a three-week period.

Another important finding was that researchers observed that tumour destruction was accompanied by an influx of immune cells. This indicates an anti-tumour immune response. This is important because current cancer treatments can kill healthy cells and suppress the body's natural ability to fight infections.

Dr Andrew Stephens, head of the Ovarian Cancer Research at Hudson Institute, spoke very positively about the results.

He said: "These results suggest that Photosoft Technology may be an effective method to achieve targeted tumour destruction. Over the coming months we will be working with the Photosoft Technology to characterise how tumour destruction and immune response are linked, paving the way for clinical trials using Photosoft Technology as a cancer therapy."

Given how badly new treatment options are needed, I can't say I'm surprised that investors are getting excited over the results. But it is worth remembering that there is still a lot of work to be done before Photosoft potentially gets to that stage. 

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Fortescue, Lynas, PEXA, and Regis Healthcare shares are charging higher

These shares are having a strong session on Thursday. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Capricorn Metals, Insignia, Perseus Mining, and Qoria shares are storming higher

These shares are having a strong session on Tuesday. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Amaero, AMP, Block, and South32 shares are racing higher today

These shares are starting the week on a positive note. But why?

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »